Phaseline

Targets › HSPG2

HSPG2 (Basement membrane-specific heparan sulfate proteoglycan core protein): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Metabolic and endocrine; next expected readout Dec 2026.

Integral component of basement membranes. Component of the glomerular basement membrane (GBM), responsible for the fixed negative electrostatic membrane charge, and which provides a barrier which is both size- and charge-selective. (UniProt, P98160)

Open in Phaseline: the race on HSPG2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of Tennessee Graduate School of Medicine99mTc-p5+14
Pan-amyloid reactive peptide that binds hypersulfated heparan sulfate glycosaminoglycans a
HSPG2Phase 1Systemic AmyloidosisDec 2026

Conditions

Systemic Amyloidosis (1)

Modalities

mixed (1)

Companies

University of Tennessee Graduate School of Medicine (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.